X
Search Filters
Format Format
Format Format
X
Sort by Item Count (A-Z)
Filter by Count
Journal Article (3825) 3825
Magazine Article (35) 35
Book / eBook (7) 7
Book Chapter (7) 7
Newsletter (7) 7
Newspaper Article (4) 4
Book Review (1) 1
more...
Subjects Subjects
Subjects Subjects
X
Sort by Item Count (A-Z)
Filter by Count
humans (3071) 3071
male (1815) 1815
female (1656) 1656
quinolones - therapeutic use (1475) 1475
quinolones - adverse effects (1425) 1425
adult (1296) 1296
middle aged (1108) 1108
pharmacology & pharmacy (1076) 1076
aripiprazole (1059) 1059
quinolones (981) 981
piperazines - therapeutic use (770) 770
antipsychotic agents - adverse effects (750) 750
quinolones - administration & dosage (749) 749
piperazines - adverse effects (745) 745
aged (734) 734
antipsychotic agents - therapeutic use (732) 732
treatment outcome (721) 721
psychiatry (713) 713
fluoroquinolones (632) 632
animals (623) 623
adolescent (533) 533
quinolones - pharmacology (494) 494
ciprofloxacin (450) 450
double-blind (445) 445
drug therapy (444) 444
double-blind method (414) 414
schizophrenia (413) 413
schizophrenia - drug therapy (402) 402
antibiotics (370) 370
drug therapy, combination (366) 366
dose-response relationship, drug (364) 364
safety (358) 358
efficacy (350) 350
quinolone antibacterial agents (337) 337
anti-infective agents - adverse effects (317) 317
infectious diseases (310) 310
dosage and administration (302) 302
young adult (287) 287
child (279) 279
quinolones - pharmacokinetics (278) 278
medicine & public health (270) 270
anti-infective agents - therapeutic use (269) 269
piperazines - administration & dosage (265) 265
research (265) 265
care and treatment (264) 264
aged, 80 and over (259) 259
microbiology (258) 258
risk factors (258) 258
pharmacokinetics (252) 252
anti-bacterial agents - adverse effects (251) 251
clinical neurology (250) 250
administration, oral (245) 245
anti-bacterial agents - therapeutic use (244) 244
drug administration schedule (244) 244
medicine, general & internal (240) 240
antipsychotic agents - administration & dosage (237) 237
analysis (235) 235
health aspects (230) 230
levofloxacin (227) 227
internal medicine (218) 218
neurosciences (216) 216
drug interactions (213) 213
respiratory system (208) 208
clinical trials (203) 203
complications and side effects (199) 199
oncology (199) 199
rats (194) 194
time factors (193) 193
pharmacology/toxicology (187) 187
therapy (187) 187
risperidone (184) 184
olanzapine (183) 183
drugs (176) 176
randomized controlled trials as topic (173) 173
prospective studies (171) 171
placebo (169) 169
pulmonary disease, chronic obstructive - drug therapy (168) 168
quinolone (168) 168
mice (162) 162
immunology (161) 161
toxicology (161) 161
ofloxacin (158) 158
pharmacotherapy (157) 157
drug resistance (156) 156
infections (155) 155
bipolar disorder - drug therapy (154) 154
microbial sensitivity tests (153) 153
psychiatric status rating scales (153) 153
atypical antipsychotics (148) 148
retrospective studies (146) 146
psychotic disorders - drug therapy (144) 144
fluoroquinolones - adverse effects (143) 143
children (142) 142
pharmacology (142) 142
risk (140) 140
anti-bacterial agents - pharmacology (138) 138
anti-infective agents - administration & dosage (138) 138
alanine - analogs & derivatives (136) 136
severity of illness index (136) 136
usage (135) 135
more...
Library Location Library Location
Language Language
Language Language
X
Sort by Item Count (A-Z)
Filter by Count
English (3764) 3764
Japanese (56) 56
French (36) 36
German (30) 30
Spanish (19) 19
Russian (12) 12
Portuguese (9) 9
Dutch (7) 7
Chinese (6) 6
Swedish (4) 4
Danish (3) 3
Hungarian (3) 3
Italian (3) 3
Korean (2) 2
Turkish (2) 2
Bulgarian (1) 1
Czech (1) 1
Norwegian (1) 1
Polish (1) 1
Ukrainian (1) 1
more...
Publication Date Publication Date
Click on a bar to filter by decade
Slide to change publication date range


Journal Article
Lancet Infectious Diseases, The, ISSN 1473-3099, 2014, Volume 14, Issue 7, pp. 581 - 589
Journal Article
The New England journal of medicine, ISSN 1533-4406, 2019, Volume 381, Issue 19, pp. 1809 - 1819
Triple treatment with elexacaftor, tezacaftor, and ivacaftor in patients with cystic fibrosis who had one Phe508del allele and a minimal-function mutation... 
TRANSMEMBRANE CONDUCTANCE REGULATOR | ADULT PATIENTS | MEDICINE, GENERAL & INTERNAL | EXACERBATIONS | FEV1 | POTENTIATOR | DECLINE | Cystic Fibrosis - physiopathology | Humans | Pyrrolidines - administration & dosage | Pyrrolidines - adverse effects | Male | Chloride Channel Agonists - adverse effects | Benzodioxoles - administration & dosage | Aminophenols - adverse effects | Indoles - administration & dosage | Forced Expiratory Volume | Sweat - chemistry | Young Adult | Pyridines - adverse effects | Quinolones - adverse effects | Adult | Benzodioxoles - adverse effects | Female | Child | Pyrazoles - adverse effects | Pyridines - administration & dosage | Double-Blind Method | Genotype | Chlorides - analysis | Pyrazoles - administration & dosage | Quinolones - administration & dosage | Indoles - adverse effects | Chloride Channel Agonists - administration & dosage | Cystic Fibrosis - genetics | Adolescent | Cystic Fibrosis Transmembrane Conductance Regulator - genetics | Mutation | Aminophenols - administration & dosage | Cystic Fibrosis - drug therapy | Drug Combinations | Cystic fibrosis | Ivacaftor | Genetic aspects | Drug therapy | Patient outcomes | Statistical analysis | Stock options | Clinical trials | Patients | Clinical outcomes | Quality of life | Proteins | Collaboration | Conductance | Genotypes | Pharmaceuticals
Journal Article
The Lancet (British edition), ISSN 0140-6736, 2015, Volume 385, Issue 9987, pp. 2606 - 2615
Summary Background Tenofovir disoproxil fumarate can cause renal and bone toxic effects related to high plasma tenofovir concentrations... 
Internal Medicine | KIDNEY-DISEASE | RATES | MEDICINE, GENERAL & INTERNAL | ABACAVIR-LAMIVUDINE | BONE-MINERAL DENSITY | SAFETY | ADULTS | ANTIRETROVIRAL THERAPY | LOPINAVIR/RITONAVIR | COUNT | EXPOSURE | Humans | Male | Thiazoles - administration & dosage | Carbamates - administration & dosage | Arthralgia - chemically induced | Thiazoles - adverse effects | Sleep Initiation and Maintenance Disorders - chemically induced | Tenofovir | Adenine - adverse effects | Quinolones - adverse effects | Adult | Anti-HIV Agents - therapeutic use | Deoxycytidine - adverse effects | Female | Headache - chemically induced | Emtricitabine | Adenine - analogs & derivatives | Kidney - drug effects | Respiration Disorders - chemically induced | Double-Blind Method | Anti-HIV Agents - adverse effects | Deoxycytidine - administration & dosage | HIV Infections - virology | Organophosphonates - adverse effects | Treatment Outcome | CD4 Lymphocyte Count | Nausea | Adenine - administration & dosage | Organophosphonates - administration & dosage | Bone Density - drug effects | Quinolones - administration & dosage | Carbamates - adverse effects | HIV Infections - drug therapy | Viral Load - drug effects | Cobicistat | Deoxycytidine - analogs & derivatives | Drug Combinations | Medical colleges | Clinical trials | Cross infection | Nosocomial infections | HIV (Viruses) | Drug therapy | Health aspects | HIV infection | Analysis | Antiretroviral drugs | Infections | Acquired immune deficiency syndrome--AIDS | Human immunodeficiency virus--HIV
Journal Article
The New England journal of medicine, ISSN 1533-4406, 2018, Volume 379, Issue 17, pp. 1599 - 1611
This companion article to the VX-445 report shows that VX-659, a new CFTR potentiator, when administered with tezacaftor and ivacaftor improved lung function,... 
G551D MUTATION | MEDICINE, GENERAL & INTERNAL | IN-VITRO | CFTR POTENTIATOR | TEZACAFTOR-IVACAFTOR | Pyrazoles - therapeutic use | Forced Expiratory Volume - drug effects | Humans | Pyrrolidines - adverse effects | Chloride Channel Agonists - therapeutic use | Male | Aminophenols - therapeutic use | Chloride Channel Agonists - adverse effects | Aminophenols - adverse effects | Pyrrolidines - pharmacology | Pyrrolidines - therapeutic use | Sweat - chemistry | Young Adult | Quinolones - adverse effects | Quinolones - therapeutic use | Adult | Benzodioxoles - adverse effects | Female | Benzodioxoles - therapeutic use | Pyrazoles - adverse effects | Pyrazoles - pharmacology | Double-Blind Method | Cells, Cultured | Genotype | Cystic Fibrosis Transmembrane Conductance Regulator - metabolism | Chlorides - analysis | Indoles - adverse effects | Cystic Fibrosis - genetics | Adolescent | Alleles | Cystic Fibrosis Transmembrane Conductance Regulator - genetics | Indoles - therapeutic use | Mutation | Cystic Fibrosis - drug therapy | Drug Combinations | Cystic fibrosis | Ivacaftor | Genetic aspects | Dosage and administration | Drug therapy | Epithelial cells | Chloride transport | Clinical trials | Recovery of function | Patients | Proteins | Genotype & phenotype | Conductance | Cystic fibrosis transmembrane conductance regulator | Protein transport | Sweat | Binding sites | Genotypes
Journal Article
JAMA : the journal of the American Medical Association, ISSN 0098-7484, 10/2009, Volume 302, Issue 16, pp. 1765 - 1773
Journal Article
Journal of clinical psychopharmacology, ISSN 0271-0749, 04/2008, Volume 28, Issue 2, pp. 156 - 165
Journal Article
PLoS medicine, ISSN 1549-1277, 03/2012, Volume 9, Issue 3, p. e1001189
Journal Article
The lancet respiratory medicine, ISSN 2213-2600, 2013, Volume 1, Issue 1, pp. 51 - 60
Journal Article
The New England journal of medicine, ISSN 1533-4406, 2017, Volume 377, Issue 21, pp. 2013 - 2023
Journal Article